BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector

H. Yamamoto, M. Ishimura, M. Ochiai, H. Takada, K. Kusuhara, Y. Nakatsu, T. Tsuzuki, K. Mitani, T. Hara

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

X-linked agammaglobulinemia (XLA) is one of the most common humoral immunodeficiencies, which is caused by mutations in Bruton's tyrosine kinase (BTK) gene. To examine the possibility of using gene therapy for XLA, we constructed a helper-dependent adenovirus/adeno-associated virus BTK targeting vector (HD-Ad.AAV BTK vector) composed of a genomic sequence containing BTK exons 6-19 and a green fluorescence protein-hygromycin cassette driven by a cytomegalovirus promoter. We first used NALM-6, a human male pre-B acute lymphoblastic leukemia cell line, as a recipient to measure the efficiency of gene targeting by homologous recombination. We identified 10 clones with the homologous recombination of the BTK gene among 107 hygromycin-resistant stable clones isolated from two independent experiments. We next used cord blood CD34+ cells as the recipient cells for the gene targeting. We isolated colonies grown in medium containing cytokines and hygromycin. We found that the targeting of the BTK gene occurred in four of the 755 hygromycin-resistant colonies. Importantly, the gene targeting was also observed in CD19+ lymphoid progenitor cells that were differentiated from the homologous recombinant CD34+ cells during growth in selection media. Our study shows the potential for the BTK gene therapy using the HD-Ad.AAV BTK vector via homologous recombination in hematopoietic stem cells.

Original languageEnglish
Pages (from-to)205-213
Number of pages9
JournalGene Therapy
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Dependovirus
Gene Targeting
Homologous Recombination
Adenoviridae
Genetic Therapy
Lymphoid Progenitor Cells
Clone Cells
Genes
Agammaglobulinaemia tyrosine kinase
Hematopoietic Stem Cells
Cytomegalovirus
Fetal Blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Exons
Blood Cells
Fluorescence
Cytokines
Cell Line
Mutation
hygromycin A

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector. / Yamamoto, H.; Ishimura, M.; Ochiai, M.; Takada, H.; Kusuhara, K.; Nakatsu, Y.; Tsuzuki, T.; Mitani, K.; Hara, T.

In: Gene Therapy, Vol. 23, No. 2, 01.02.2016, p. 205-213.

Research output: Contribution to journalArticle

Yamamoto, H. ; Ishimura, M. ; Ochiai, M. ; Takada, H. ; Kusuhara, K. ; Nakatsu, Y. ; Tsuzuki, T. ; Mitani, K. ; Hara, T. / BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector. In: Gene Therapy. 2016 ; Vol. 23, No. 2. pp. 205-213.
@article{02178bcd0fa34d21b99bfeed8790936b,
title = "BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector",
abstract = "X-linked agammaglobulinemia (XLA) is one of the most common humoral immunodeficiencies, which is caused by mutations in Bruton's tyrosine kinase (BTK) gene. To examine the possibility of using gene therapy for XLA, we constructed a helper-dependent adenovirus/adeno-associated virus BTK targeting vector (HD-Ad.AAV BTK vector) composed of a genomic sequence containing BTK exons 6-19 and a green fluorescence protein-hygromycin cassette driven by a cytomegalovirus promoter. We first used NALM-6, a human male pre-B acute lymphoblastic leukemia cell line, as a recipient to measure the efficiency of gene targeting by homologous recombination. We identified 10 clones with the homologous recombination of the BTK gene among 107 hygromycin-resistant stable clones isolated from two independent experiments. We next used cord blood CD34+ cells as the recipient cells for the gene targeting. We isolated colonies grown in medium containing cytokines and hygromycin. We found that the targeting of the BTK gene occurred in four of the 755 hygromycin-resistant colonies. Importantly, the gene targeting was also observed in CD19+ lymphoid progenitor cells that were differentiated from the homologous recombinant CD34+ cells during growth in selection media. Our study shows the potential for the BTK gene therapy using the HD-Ad.AAV BTK vector via homologous recombination in hematopoietic stem cells.",
author = "H. Yamamoto and M. Ishimura and M. Ochiai and H. Takada and K. Kusuhara and Y. Nakatsu and T. Tsuzuki and K. Mitani and T. Hara",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/gt.2015.91",
language = "English",
volume = "23",
pages = "205--213",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector

AU - Yamamoto, H.

AU - Ishimura, M.

AU - Ochiai, M.

AU - Takada, H.

AU - Kusuhara, K.

AU - Nakatsu, Y.

AU - Tsuzuki, T.

AU - Mitani, K.

AU - Hara, T.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - X-linked agammaglobulinemia (XLA) is one of the most common humoral immunodeficiencies, which is caused by mutations in Bruton's tyrosine kinase (BTK) gene. To examine the possibility of using gene therapy for XLA, we constructed a helper-dependent adenovirus/adeno-associated virus BTK targeting vector (HD-Ad.AAV BTK vector) composed of a genomic sequence containing BTK exons 6-19 and a green fluorescence protein-hygromycin cassette driven by a cytomegalovirus promoter. We first used NALM-6, a human male pre-B acute lymphoblastic leukemia cell line, as a recipient to measure the efficiency of gene targeting by homologous recombination. We identified 10 clones with the homologous recombination of the BTK gene among 107 hygromycin-resistant stable clones isolated from two independent experiments. We next used cord blood CD34+ cells as the recipient cells for the gene targeting. We isolated colonies grown in medium containing cytokines and hygromycin. We found that the targeting of the BTK gene occurred in four of the 755 hygromycin-resistant colonies. Importantly, the gene targeting was also observed in CD19+ lymphoid progenitor cells that were differentiated from the homologous recombinant CD34+ cells during growth in selection media. Our study shows the potential for the BTK gene therapy using the HD-Ad.AAV BTK vector via homologous recombination in hematopoietic stem cells.

AB - X-linked agammaglobulinemia (XLA) is one of the most common humoral immunodeficiencies, which is caused by mutations in Bruton's tyrosine kinase (BTK) gene. To examine the possibility of using gene therapy for XLA, we constructed a helper-dependent adenovirus/adeno-associated virus BTK targeting vector (HD-Ad.AAV BTK vector) composed of a genomic sequence containing BTK exons 6-19 and a green fluorescence protein-hygromycin cassette driven by a cytomegalovirus promoter. We first used NALM-6, a human male pre-B acute lymphoblastic leukemia cell line, as a recipient to measure the efficiency of gene targeting by homologous recombination. We identified 10 clones with the homologous recombination of the BTK gene among 107 hygromycin-resistant stable clones isolated from two independent experiments. We next used cord blood CD34+ cells as the recipient cells for the gene targeting. We isolated colonies grown in medium containing cytokines and hygromycin. We found that the targeting of the BTK gene occurred in four of the 755 hygromycin-resistant colonies. Importantly, the gene targeting was also observed in CD19+ lymphoid progenitor cells that were differentiated from the homologous recombinant CD34+ cells during growth in selection media. Our study shows the potential for the BTK gene therapy using the HD-Ad.AAV BTK vector via homologous recombination in hematopoietic stem cells.

UR - http://www.scopus.com/inward/record.url?scp=84956943169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956943169&partnerID=8YFLogxK

U2 - 10.1038/gt.2015.91

DO - 10.1038/gt.2015.91

M3 - Article

C2 - 26280081

AN - SCOPUS:84956943169

VL - 23

SP - 205

EP - 213

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 2

ER -